Available online on 15 Sep, 2024 at https://ijdra.com/index.php/journal
International Journal of Drug Regulatory Affairs
Published by Diva Enterprises Pvt. Ltd., New Delhi
Associated with RAPS & Delhi Pharmaceutical Sciences & Research University

Review Article Open Access

A Review on a Drug Registration Process in United Kingdom

Yash B. Kulkarni* Lokesh P. Kothari

Department of Regulatory Affairs, SNJBs Shriman Sureshdada Jain College of Pharmacy Chandwad, Dist. Nashik, Maharashtra, India.

Abstract

This review outlines the regulatory modifications in several pharmaceutical industries that have been impacted by Brexit and develops new standards-based recommendations from the Medicines and Healthcare Products Regulatory Agency (MHRA). To get insight into the regulatory changes that occurred in the pharmaceutical industry during the dissolution of Europe and Britain, retrospective and contemporaneous reviews were used. As the transition period concluded, the MHRA issued a library of new guidelines on January 1, 2021. The several pharmaceutical industries covered by this guidance include clinical trials, medical equipment, imports and exports of Pharmaceuticals and Cosmetics. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for approving medicinal products in the UK. The agency offers various routes for marketing authorisation, including national, international, and decentralised procedures. The national routes include a 150-day assessment, rolling review, European Commission (EC) Decision Reliance Procedure, decentralised and mutual recognition reliance procedure, and unfettered access procedure for marketing authorisations approved in Northern Ireland. International routes include Project Orbis and Access Consortium. Applicants must submit their applications through the MHRA submissions portal in electronic Common Technical Document (eCTD) format. The agency verifies the technical validity of submissions using the Lorenz Docubridge validation tool. The MHRA offers fast-track marketing authorisation for products with strong public health benefits or those addressing supply shortages. Applications that do not meet guidelines will be rejected, and applicants must resubmit after correcting errors. Understanding MHRA guidelines and requirements facilitates market entry for medicinal products in the UK.

Conclusion: Any medicinal agent to be marked in the United Kingdom has to follow the guidelines and regulations given by the MHRA a regulatory authority which approve drug products.

The objective of the review article is to highlights information regarding the requirements. Different types routes in registration of medicinal products in a market in the United Kingdom knowing the requirements of the MHRA guidelines, it is too easy for a product to get into the UK market.

Keywords: MHRA, Medicine, Project Orbis, Access Consortium, Marketing Authorization, SPC Template, Regulatory Authority.

Article Info: Received 12 Jul 2024; Review Completed 26 Aug 2024; Accepted 15 Sep 2024

Cite this article as:
Kulkarni YB, Kothari LP. A Review on a Drug Registration Process in United Kingdom. Int. J. Drug Reg. Affairs [Internet]. 2024 Sep15 [cited 2024 Sep 15]; 12(3):32-37. Available from: http://ijdra.com/index.php/journal/article/view/691

DOI: https://doi.org/10.22270/ijdra.v12i3.691
*Corresponding author

1. Introduction

The UK's medicines and healthcare products regulatory body (MHRA) oversees the approval of medications, medical devices, and other medical items. The agency protects and improves public health and promotes all advances through scientific research and development programmes. The agency operates three centres.

- The Clinical Practice Research Datalink (CPRD), a data research service which improve public health Service with the help of NHS clinical data.
- The National Institute for Biological Standards and Control (NIBSC) which is a worldwide maintaining the standards and Control of biological products.
- The Medicines and Healthcare Products Regulatory Agency (MHRA) which is the UK administrative body for medicines, medical devices and blood transfusion and furthermore quality and viability of pharmaceuticals.

Not every drug can be regarded as suitable for consumption. The medication may be helpful in certain situations, but it may also have fatal side effects in other

situations. People react differently to different medications. Severe side effects are occasionally possible with medications. The following treatment conditions and prescription doses have an impact on the adverse effects. Any medicine that wants to be sold will need to obtain a licence.

Functions of MHRA: - Clinical Trail Regulations, Monitoring the safety and efficacy of drugs Licensing, implement law, provide guidance and information to public.

License Process: In the UK, Great Britain (England, Scotland, and Wales), or Northern Ireland, there are multiple ways to get a marketing authorization. The target market and application type will dictate the available possibilities.

1.1 National routes

1) 150-day assessment for national applications for medicines.

2) Rolling review for marketing authorisation applications.

3) European Commission (EC) Decision Reliance Procedure.

4) Decentralised and Mutual recognition reliance procedure for Marketing authorisations.

5) Unfettered Access Procedure for marketing authorisations approved in North Ireland.

1.2 International routes (collaborative procedures) Project Orbis and Access Consortium. (1)

2. Types of application (legal basis)

Applicant must include the appropriate type of application when apply to MHRA for a marketing authorisation. Applicant must know what type formulation or drug want market. The appropriate legal basis will depend the type of application applicant are making. The legal bases are:

- Complete implementation of Regulation 50 (formerly Directive 2001/83/EC, Article 8(3)).
- General application: Article 10.1 of Directive 2001/83/EC was replaced by Regulation 51 (application for UKMA(NI); Regulation 51A (application for UKMA(GB)); and Regulation 51B (application for UKMA(UK)).
- Hybrid applications: Article 10.3 of Directive 2001/83/EC was replaced by Regulation 52 (application for UKMA(NI)), Regulation 52A (application for UKMA(GB)), and Regulation 52B (application for UKMA(UK)).
- Similar biological application: Article 10.4 of Directive 2001/83/EC was replaced by Regulations 53 (application for UKMA(NI)), 53A (application for UKMA(GB)), and 53B (application for UKMA(UK)).
- Application for well-established usage - Regulation 54 (formerly Directive 2001/83/EC Article 10a)
- Regulation 55, fixed-combination application (formerly Article 10b of Directive 2001/83/EC)
- Application for informed consent - Regulation 56 (formerly Directive 2001/83/EC Article 10c)
- Conventional herbal registrations under Regulation 127 (formerly under Directive 2001/83/EC Article 16a)
- Homoeopathic medicine certificates (also known as the Simplified Registration method) Regulation 50(6)(g) and Schedule 10 (formerly Article 16(2) of Directive 2001/83/EC)(2); Regulation 103 (formerly Article 14(1) of Directive 2001/83/EC) national homoeopathic goods (also known as the National Rules Scheme). (2)

3. Application procedure

Use the MHRA submissions portal to submit all national applications for the United Kingdom and Great Britain (England, Scotland, and Wales). mhra accept electronic Common Technical Document (eCTD) format for submission. make sure that eAF and cover letter is use. application rejected if the necessary information isn't included. Using the Lorenz Docubridge validation tool, which rigorously aligns validation against ICH worldwide standards and eCTD 3.2 regional requirements, mhra verify the technical validity of eCTD submissions. The LORENZ eValidator Basic validation software for eCTD.

PL Number: Ireland licence, Applicant get a PL number from MHRA authority before sponsor submitting application.

PL: a product licensed by the MHRA that covers the whole of the UK, coming into effect from 1 January 2025

PLNI: a product licensed by the MHRA that covers Northern Ireland (NI) only as the territorial application.

PLGB: a product licensed by the MHRA that covers Great Britain (GB) only as the territorial application.

a) Active Substance Master File: ASMF should contain detail scientific information as under heading to applicant for marketing authorization**.** The MHRA must receive the dossier from holders of active substance master files (ASMFs). applicant to ensure sure the ASMF is submitted, either concurrently with or prior to your application. It is necessary for your application to be valid. A new ASMF should be submitted using MHRA Submissions, as should any updates to an existing ASMF. Certificates of appropriateness (CEPs), in support of UK and GB national authorizations.

b) Summary of product characteristics: Characteristic summary of the product (SmPC) should be submitted to the MHRA using the SPC Template in the appropriate format. (3)

6.150-days assessment national application for medicine: The Medicines and Healthcare products Regulatory Agency (MHRA) offers an expedited assessment process for high-quality marketing authorisation applications (MAAs), thereby facilitating earlier access to novel therapies for patients in the United

Kingdom. This accelerated process ensures that applications for marketing authorisation, encompassing new active substances, biosimilar products, and existing active substances, are evaluated and opinions on approvability rendered within a 150-day timeframe from the date of valid application submission. All applications must be submitted via the MHRA's designated online portal. (4)



Figure 1. Terminology of the British Isles (5)

4. Rolling review for marketing authorisation applications:

The rolling review process offers a novel approach for submitting marketing authorisation applications (MAAs), whereby applicants can submit individual modules of the electronic Common Technical Document (eCTD) dossier for pre-assessment, rather than a complete dossier. This incremental approach enables the Medicines and Healthcare products Regulatory Agency (MHRA) to provide periodic regulatory feedback and guidance, streamlining the development of innovative medicines and reducing the risk of failure in the final stages. By integrating the rolling review with the Target Development Profile (TDP), a clearer pathway for the development of novel therapies can be established, fostering a more efficient and effective regulatory process. (6)

5. European Commission (EC) Decision Reliance Procedure:

The European Commission (EC) Decision Reliance Procedure enables the Medicines and Healthcare products Regulatory Agency (MHRA) to rely on EC decisions regarding marketing authorisation (MA) approval via the centralised procedure. This procedure, known as the EC Decision Reliance Procedure (ECDRP), applies to MAs approved through the centralised route. Upon receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), applicants can submit their Marketing Authorisation Application (MAA) to the MHRA, which aims to grant a Great Britain MA as soon as possible after EC approval. While applications can be submitted at any time after EU Marketing Authorisation approval, delays may impact the MHRA's ability to deliver a decision within the 67-day timeline. (7)



Figure 2. Drug Approval Process in the United Kingdom

6. Decentralised and Mutual recognition reliance procedure for Marketing authorisations

Medicines and Healthcare products Regulatory Agency (MHRA) has the authority to consider Marketing Authorisations (MAs) approved in European Union Member States, as well as Iceland, Liechtenstein, and Norway, through decentralised and mutual recognition procedures. This enables the MHRA to leverage existing approvals and grant MAs in the UK or Great Britain (England, Scotland, and Wales) in a streamlined manner. The goal is to complete this process within 67 days of Marketing Authorisation Application (MAA) validation, facilitating a more efficient regulatory process. (8)

7. Unfettered Access Procedure for marketing authorisations approved in North Ireland

The Unfettered Access Procedure (UAP) enables Marketing Authorisations (MAs) approved in Northern Ireland or European Union/European Economic Area (EU/EEA) member states to be recognized in Great Britain (England, Scotland, and Wales) for product marketing. Through this procedure, Marketing Authorisation Applications (MAAs) are eligible for recognition by the Medicines and Healthcare products Regulatory Agency (MHRA) within 67 days of validation, unless significant concerns (Major Objections) are identified. This streamlined process facilitates access to the Great Britain market for products already approved in Northern Ireland or the EU/EEA. (9)

8. International Routes

8.1 Project Orbis

The programme provides a framework for concurrent submission and review of oncology related medicinal products among international partners. It aims to faster patient access to innovative cancer treatments with potential benefits over existing therapies. Project Orbis is collaborated by the US Food and Drug Administration (FDA). Alongside MHRA, it involves the regulatory authorities of:

- Australia (Therapeutic Goods Administration (TGA))
- Canada (Health Canada)
- Singapore (Health Sciences Authority (HSA))
- Switzerland (Swissmedic)
- Brazil (Agência Nacional de Vigilância Sanitária (ANVISA))
- Israel (Ministry of Health)

Project Orbis Partners (POPs) may refer products for inclusion in the scheme. Each country remains fully independent on their final authority decision. (10)

8.2 Access Consortium

The Access Consortium is a collaboration of regulatory agencies, including the MHRA, Therapeutic Goods Authority Australia, Health Canada, Health Sciences Authority Singapore, and Swissmedic, working together to enhance regulatory alignment and cooperation. Formed in 2007 as ACSS, the consortium expanded to include the MHRA in 2020 and was renamed Access. The goal is to maximize international cooperation, reduce duplication, and increase capacity to ensure timely access to high-quality, safe, and effective therapeutic products. With the increasing globalization of the industry and rapid technological advancements, regulatory bodies need to cooperate and share expertise to ensure a consistent approach to evaluating benefits and risks. The Access Consortium has established various working groups, including those focused on new active substances, generic medicines, biosimilars, ICH, IT architecture, and advanced therapy medicinal products, to facilitate collaboration and knowledge sharing. The original consortium, formed 'ACSS', In October 2020, the MHRA joined, and the group's title was changed to 'Access'. The MHRA will commence work-sharing applications with Get to accomplices from 1 January 2021.The consortium's objective is to expand universal co-operation between accomplices in the consortium, decrease duplication, and increase for administrative bodies to co-operate and communicate with each other routinely.. The trend towards globalisation of Pharmaceutical products industries and the rapid emergence of new tech innovation in the last few years accompanied with shared global challenges and increased need for regulatory bodies to co-operate and Access working groups. (11)

8.3 Fast-track your marketing authorisation

Obtain your marketing authorization more quickly: Applications may be processed more quickly if there is strong proof of a public health emergency's benefit or if the Department of Health and Social Care (DHSC) has confirmed that there is a shortage of a necessary medication.to ask for assistance in accelerating your marketing.

- the rationale behind quick tracking.
- A succinct summary of the product's main therapeutic attributes
- proof that the product offers the promised advantages for the suggested indication(s)

Because of a supply shortfall, we advise applicants to expedite their applications. You can do this by emailing DHSC. Applications for fast-tracking are not subject to an extra charge.

Rejection: Submissions that do not adhere to the guidelines will be disqualified. In the event that a submission is denied, MHRA will give you the reasoning behind the decision. After the errors have been fixed, the applicant must resend the full submission. Please refrain from emailing the fixed flaws. If an applicant's submission is denied for technical reasons, MHRA won't be billed. (12)

9. Conclusion

Any medicinal agent to be marked in the United Kingdom has to follow the guidelines and regulations given by the MHRA a regulatory authority which approve drug products.

The objective of the review article is to highlights information's regarding the requirements. Different types routes in registration of medicinal products in a market in the United Kingdom knowing the requirements of the MHRA guidelines, it is easy for a product to get into the UK market**.**

Acknowledgement: The authors are very much thankful to management and principal of SNJB's Shreeman Sureshdada Jain College of Pharmacy, Neminagar, Chandwad.

Financial Disclosure statement: The author received no specific funding for this work.

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

References

1. Medicines and Healthcare products Regulatory Agency. "Licensing: how to apply" [Internet]. gov.uk; 2021 May 04 [cited 2024 Apr 02]. Available from: https://www.gov.uk/government/collections/licencing-how-to-apply
2. Medicines and Healthcare products Regulatory Agency "types of application legal basis" [Internet]. gov.uk; 2021 May 04 [cited 2024 Apr 02]. Available from: https://www.gov.uk/guidance/types-of-application-legal-basis
3. Medicines and Healthcare products Regulatory Agency" Apply for a licence to market a medicine in the UK" [Internet]. gov.uk;2024 Dec 18 [cited 2024 Apr 02]. Available from: https://www.gov.uk/guidance/apply-for-a-licence-to-market-a-medicine-in-the-uk
4. Medicines and Healthcare products Regulatory Agency. "150-day assessment for national applications for medicines" [Internet]. gov.uk;2024 Apr 16 [cited 2024 Apr 02]. Available from: https://www.gov.uk/guidance/guidance-on-150-day-assessment-for-national-applications-for-medicines
5. Admin, Admin. UK and Great Britain Map - Ashlan Ninnetta - Explore ideas, tips guide and info. [Internet]. Ashlan Ninnetta; 2023 [cited 2024 Apr 02]. Available from: https://myrillaotori.pages.dev/wpavb-uk-and-great-britain-map-ggkap-photos/

6. Medicines and Healthcare products Regulatory Agency. "Rolling review for marketing authorisation applications" [Internet]. gov.uk;2024 Apr 16 [cited 2024 Apr 02]. Available from: https://www.gov.uk/guidance/rolling-review-for-marketing-authorisation-applications
7. Medicines and Healthcare products Regulatory Agency. "European Commission (EC) decision reliance procedure" [Internet]. gov.uk;2022 Nov 18 [cited 2024 Apr 02]. Available from: https://www.gov.uk/guidance/european-commission-ec-decision-reliance-procedure
8. Medicines and Healthcare products Regulatory Agency. Decentralised and mutual recognition reliance procedure for marketing authorisations [Internet]. gov.uk;2021 Feb 23 [cited 2024 Apr 02]. Available from: https://www.gov.uk/guidance/decentralised-and-mutual-recognition-reliance-procedure-for-marketing-authorisations
9. Medicines and Healthcare products Regulatory Agency. "Unfettered Access Procedure for marketing authorisations approved in Northern Ireland" [Internet]. gov.uk;2024 Jan 05 [cited 2024 Apr 02]. Available from: https://www.gov.uk/guidance/unfettered-access-procedure-for-marketing-authorisations-approved-in-northern-ireland
10. Medicines and Healthcare products Regulatory Agency. "Project Orbis" [Internet]. gov.uk; 2024 Jan 12 [cited 2024 Apr 02]. Available from: https://www.gov.uk/guidance/guidance-on-project-orbis
11. Medicines and Healthcare products Regulatory Agency. "Access Consortium" [Internet]. gov.uk; 2024 Feb 26 [cited 2024 Apr 02]. Available from: https://www.gov.uk/guidance/access-consortium
12. Medicines and Healthcare products Regulatory Agency. "Apply for a licence to market a medicine in the UK" [Internet]. gov.uk;2024 May 14 [cited 2024 May 30]. Available from: https://www.gov.uk/guidance/apply-for-a-licence-to-market-a-medicine-in-the-uk#fast-track-your-marketing-authorisation